Surrozen, Inc. (SRZN) Stock

Surrozen, Inc. (SRZN) is a Healthcare stock trading at $23.50 (as of 2026-06-18), with a market capitalization of $304.31M and a trailing P/E of -0.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Surrozen, Inc. is a biotechnology company developing drug candidates that selectively modulate the Wnt signaling pathway, including tissue-targeted antibody approaches. Its pipeline includes SZN-043, a tissue-specific R-spondin mimetic for severe liver disease, and SZN-1326, a bispecific human antibody targeting receptors involved in Wnt signaling in intestinal crypts, with potential applications across multiple disease areas.

Valuation — source: SEC EDGAR (first-party)
Price	$23.50
Market Cap	$304.31M
P/E Ratio	-0.7
EV / EBITDA	-4.6
Price / Book	-1.09
Price / Sales	40.61
DCF Value (model)	$-37.18
DCF Upside vs Price	-258.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.48M
Net Margin	-6960.8%
Return on Equity	123.2%
Current Ratio	11.91
Revenue Growth (YoY)	-67.4%
EPS Growth (YoY)	49.4%
FCF Growth (YoY)	72.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.29 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-103.4%
vs Industry	-104.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Column Group LLC ($55.84M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Craig C. Parker
Employees	40
Country	US
IPO Date	2021-01-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.